BACKGROUND: The aim of this study was to investigate whether the presence of benign or malignant nodular thyroid disease affects levels of circulating angiogenesis cytokines. METHODS: In this study we investigated levels of angiopoietin - 1 and -2 (Ang-1 and Ang-2 respectively), vascular endothelial growth factor -A (VEGF-A), galectin-3 (Gal-3), urokinase plasminogen activator receptor (uPAR) and plasminogen activation inhibitor - 1 (PAI-1) in 40 patients with differentiated thyroid cancer (DTC), 45 with thyroid papillary microcarcinoma (mPTC), 53 patients with multinodular goiter (MNG) and 58 controls. Six months after surgery 28 patients resubmitted blood samples. The diagnostic value of Ang-1 levels was evaluated with receiver operating characteristic (ROC) curves. Results: Statistically significant lower levels of Ang-1 were observed in DTC and MNG patients compared to controls (p<.05). No significant differences were observed in the levels of the other factors. The area under ROC curves for Ang-1 discerning DTC, mPTC and MNG from control were 0.68, 0.66 and 0.71 respectively. A significant increase in Ang-1 levels (p<.05) was documented in the subset of patients that underwent thyroidectomy. Thyroidectomy did not influence levels of the other factors. CONCLUSIONS: Our results suggest an association between low levels of Ang-1 and the presence of underlying benign or malignant nodular thyroid disease.
Decreased circulating levels of angiopoietin - 1 (Ang-1) are associated with the presence of multinodular goiter or differentiated thyroid cancer.
循环中血管生成素-1 (Ang-1) 水平降低与多结节性甲状腺肿或分化型甲状腺癌的发生有关
阅读:5
作者:Nixon Alexander M, Provatopoulou Xenia, Kalogera Eleni, Bletsa Garyfalia, Zografos George N, Bouklas Dimitrios, Kostopoulou Akrivi, Philippou Anastasios, Koutsilieris Michael
| 期刊: | Surgery in Practice and Science | 影响因子: | 0.800 |
| 时间: | 2023 | 起止号: | 2023 May 6; 13:100176 |
| doi: | 10.1016/j.sipas.2023.100176 | 研究方向: | 肿瘤 |
| 疾病类型: | 甲状腺癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
